InBioGen Co Ltd (KO:101140) — Market Cap & Net Worth
Market Cap & Net Worth: InBioGen Co Ltd (101140)
InBioGen Co Ltd (KO:101140) has a market capitalization of $36.20 Million (₩53.42 Billion) as of August 1, 2026. Listed on the KO stock exchange, this Korea-based company holds position #23046 globally and #1494 in its home market, demonstrating a 3.48% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying InBioGen Co Ltd's stock price ₩5350.00 by its total outstanding shares 9984772 (9.98 Million). See InBioGen Co Ltd (101140) capital reinvestment to understand how much of operating cash flow is reinvested back into capital assets.
InBioGen Co Ltd Market Cap History: 2015 to 2026
InBioGen Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $10.62 Million to $36.20 Million (12.90% CAGR).
InBioGen Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how InBioGen Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.01x
InBioGen Co Ltd's market cap is 0.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.00x
InBioGen Co Ltd's market cap is 0.00 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $10.62 Million | $8.86 Billion | -$5.69 Billion | 0.00x | N/A |
| 2016 | $13.87 Million | $11.55 Billion | -$2.26 Billion | 0.00x | N/A |
| 2017 | $18.00 Million | $7.08 Billion | -$1.21 Billion | 0.00x | N/A |
| 2018 | $33.16 Million | $7.57 Billion | $1.66 Billion | 0.00x | 0.02x |
| 2019 | $20.20 Million | $9.80 Billion | $13.12 Billion | 0.00x | 0.00x |
| 2020 | $35.46 Million | $10.22 Billion | -$45.08 Billion | 0.00x | N/A |
| 2021 | $24.09 Million | $10.48 Billion | $94.12 Billion | 0.00x | 0.00x |
| 2022 | $5.24 Million | $11.40 Billion | -$119.69 Billion | 0.00x | N/A |
| 2023 | $63.20 Million | $6.24 Billion | $11.34 Billion | 0.01x | 0.01x |
| 2024 | $63.20 Million | $7.04 Billion | $16.12 Billion | 0.01x | 0.00x |
Competitor Companies of 101140 by Market Capitalization
Companies near InBioGen Co Ltd in the global market cap rankings as of August 1, 2026.
Key companies related to InBioGen Co Ltd by market ranking:
- Nike Inc (NYSE:NKE): Ranked #538 globally with a market cap of $50.03 Billion USD.
- adidas AG (F:ADS): Ranked #836 globally with a market cap of $32.11 Billion USD ( €27.46 Billion EUR).
- adidas AG (F:ADS1): Ranked #1075 globally with a market cap of $24.65 Billion USD ( €21.09 Billion EUR).
- ASICS CORP.(UNSP.ADR)/1 (F:ASI): Ranked #1463 globally with a market cap of $17.00 Billion USD ( €14.54 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #538 | Nike Inc | NYSE:NKE | $50.03 Billion | $41.71 |
| #836 | adidas AG | F:ADS | $32.11 Billion | €160.00 |
| #1075 | adidas AG | F:ADS1 | $24.65 Billion | €81.00 |
| #1463 | ASICS CORP.(UNSP.ADR)/1 | F:ASI | $17.00 Billion | €23.80 |
InBioGen Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, InBioGen Co Ltd's market cap moved from $10.62 Million to $ 36.20 Million, with a yearly change of 12.90%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩36.20 Million | -49.00% |
| 2025 | ₩70.98 Million | +12.31% |
| 2024 | ₩63.20 Million | 0.00% |
| 2023 | ₩63.20 Million | +1105.16% |
| 2022 | ₩5.24 Million | -78.23% |
| 2021 | ₩24.09 Million | -32.06% |
| 2020 | ₩35.46 Million | +75.54% |
| 2019 | ₩20.20 Million | -39.08% |
| 2018 | ₩33.16 Million | +84.21% |
| 2017 | ₩18.00 Million | +29.76% |
| 2016 | ₩13.87 Million | +30.57% |
| 2015 | ₩10.62 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 1st, 2026 the market cap of InBioGen Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $36.20 Million USD |
| MoneyControl | $36.20 Million USD |
| MarketWatch | $36.20 Million USD |
| marketcap.company | $36.20 Million USD |
| Reuters | $36.20 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About InBioGen Co Ltd
INBIOGEN Co., Ltd. engages in the manufacture and distribution of footwear products in South Korea. It is also involved in distribution of wood pellets; kiosk; and food and beverage businesses. The company was formerly known as BTONE CO.,Ltd. INBIOGEN Co., Ltd. was founded in 1949 and is headquartered in Seoul, South Korea.